Latest Regulatory Clearance News

Page 4 of 38
New Hope has agreed to acquire the Malabar shares it does not already own in an all-scrip deal valuing Malabar at about A$1.8 billion. The transaction would give New Hope full control of the ramping Maxwell underground mine and create a coal group targeting roughly 19Mtpa of saleable production.
Maxwell Dee
Maxwell Dee
19 Oct 2026
Ampol's third-quarter trading strengthened as Lytton refinery margins more than doubled and Convenience Retail sales surged, but extra maintenance will reduce expected fourth-quarter higher-value product output by about 150 million litres. The Ultra Low Sulfur Fuels project has also slipped into the first quarter of 2027, while the proposed Evie Networks acquisition awaits regulatory clearance.
Maxwell Dee
Maxwell Dee
19 Oct 2026
Firebrick Pharma has secured Philippine marketing approval for Nasodine Nasal Spray as an over-the-counter antiseptic, opening a potential launch in the 116 million-person market from early 2027. The approval remains subject to post-approval documentation and future revalidation.
Victor Sage
Victor Sage
16 Oct 2026
SkyCity has signed a conditional agreement to sell The Grand Hotel and its business assets for $221 million, converting a previously proposed transaction into a binding deal. The proceeds are intended to repay debt, although completion still depends on Overseas Investment Office consent and other conditions.
Victor Sage
Victor Sage
16 Oct 2026
Euroz Hartleys says several conditions for its A$145 million sale of the Capital Markets business to BMO have now been satisfied, leaving shareholder approval and Canadian Bank Act approval among the key remaining gates. Completion remains on track for the December quarter.
Claire Turing
Claire Turing
14 Oct 2026
EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.
Victor Sage
Victor Sage
12 Oct 2026
HealthCo Healthcare and Wellness REIT has signed binding agreements for new leases covering its remaining 10 Healthscope hospitals, subject to final approvals. The resolution allows HCW to reinstate quarterly distributions while reducing its largest tenant concentration from 57% to 31%.
Eva Park
Eva Park
5 Oct 2026
Ampol will acquire Evie Networks for $225 million in a debt-funded deal that would more than triple its public charging footprint to approximately 1,425 bays. The transaction offers a faster route into Australia’s expanding EV infrastructure market, but its earnings case depends on regulatory clearance, integration and rising utilisation.
Maxwell Dee
Maxwell Dee
1 Oct 2026
Heartland shareholders have overwhelmingly approved the proposed acquisition of TSB and the creation of TSB Heartland Bank, advancing the transaction toward regulatory completion. The deal still faces outstanding conditions, including a Material Adverse Change test and required approvals.
Victor Sage
Victor Sage
1 Oct 2026
Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
Victor Sage
30 Sept 2026
Warburg Pincus has lifted its non-binding proposal for Ingenia Communities to $5.25 cash per stapled security, but the revised approach remains conditional on due diligence, board support and financing. Ingenia has not recommended the offer and says no transaction is certain.
Eva Park
Eva Park
28 Sept 2026
Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.
Victor Sage
Victor Sage
25 Sept 2026

Browse the archive

Full archive